CAJ | 학술논문

特立帕肽是一种注射用人重组甲状旁腺素,已在全球范围内被批准用于治疗骨质疏松症,在2011年进入中国.临床前研究显示,通过不同于包括双膦酸盐、选择性雌激素受体调节剂(selective estrogen receptor modulators,SERMs)、降钙素和雌激素在内的其他抗骨吸收药物的独特作用机制,特立帕肽可起到促进骨形成的作用.在男性和绝经后妇女中进行的临床试验已证实特立帕肽有成骨作用,并可降低骨折风险,升高骨转换标志物(包括血清骨钙素和Ⅰ型前胶原N末端肽[procollagen type Ⅰ N-terminal propeptide,PINP]、骨密度[bone mineral density,BMD])及改善骨质量.最近,在亚裔人群中进行的临床试验也已得出相似结论,并证实与目前的抗骨吸收药物相比,特立帕肽可提高骨标志物和骨密度.
특립파태시일충주사용인중조갑상방선소,이재전구범위내피비준용우치료골질소송증,재2011년진입중국.림상전연구현시,통과불동우포괄쌍련산염、선택성자격소수체조절제(selective estrogen receptor modulators,SERMs)、강개소화자격소재내적기타항골흡수약물적독특작용궤제,특립파태가기도촉진골형성적작용.재남성화절경후부녀중진행적림상시험이증실특립파태유성골작용,병가강저골절풍험,승고골전환표지물(포괄혈청골개소화Ⅰ형전효원N말단태[procollagen type Ⅰ N-terminal propeptide,PINP]、골밀도[bone mineral density,BMD])급개선골질량.최근,재아예인군중진행적림상시험야이득출상사결론,병증실여목전적항골흡수약물상비,특립파태가제고골표지물화골밀도.
Teriparatide is an injectable recombinant human parathyroid hormone (1-34) [rhPTH(1-34)],which has been approved for the treatment of osteoporosis worldwide,including China since 2011.In pre-clinical studies,teriparatide was shown to exhibit anabolic effects on bone with a unique mechanism of action that is distinct from that of antiresorptive agents,including bisphosphonates,selective estrogen receptor modulators (SERMs),calcitonin,and estrogen.This bone-building effect has been supported by clinical trials in men and postmenopausal women,with reductions in fracture risk,and increases in bone turnover markers,including serum osteocalcin and procollagen type Ⅰ N-terminal propeptide (PINP),and bone mineral density (BMD),and improvements in bone quality.Recent studies in Asian patient populations show similar results and support the findings for bone markers and BMD when compared with current antiresorptive medications.